anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Normal Healthy Adults:

The maximum recommended dose of lidocaine hydrochloride topical solution should be such that the dose of lidocaine hydrochloride is kept below 300 mg and in any case should never exceed 4.5 mg/kg (2 mg/lb) of body weight.

Children:

It is difficult to recommend a maximum dose of any drug for children since this varies as a function of age and weight. For children of less than ten years who have a normal lean body mass and normal body development, the maximum dose may be determined by the application of one of the standard pediatric drug formulas (e.g., Clark’s rule). For example, in a child of five years weighing 50 lbs., the dose of lidocaine should not exceed 75-100 mg when calculated according to Clark’s rule. In any case, the maximum dose of lidocaine hydrochloride and epinephrine should not exceed 7 mg/kg (3.2 mg/lb) of body weight. When used without epinephrine, the amount of lidocaine hydrochloride administered should be such that the dose is kept below 300 mg and in any case should not exceed 4.5 mg/kg (2.0 mg/lb) of body weight.
This study will be carried out in Lady willingdon Hospital, Lahore. In this study, we will recruit middle-aged and elderly diabetic women who have been assigned to open abdominal hysterectomy due to different gynaecological reasons. This cohort is at great risk of surgical site infection and other risk factors of SSI like hypertension, hepatitis and malignancy may coexist in these women. The study period will span to include three hundred participants as calculated according to sample size. The women will be divided into either an I\&S group or a control group by a simple random number container method. The women in the I\&S group will be inserted with bilateral drains during surgery in subcutaneous tissue after the closure of the rectus sheath and irrigated with saline followed by suction through syringe suction attached to the wound for rest of the day. The procedure will continue for three days. On the fourth day, drains are removed and stitches are removed on the fourth postoperative day. In the control group, the wound will be closed by interrupted stitches without the insertion of subcutaneous drains. The dressing will be done daily for seven days. patients with no symptoms and signs of SS will be sent home on the eighth postoperative day. The patients will be followed for symptoms of SSI, pain, readmission rate, and other complications at 4,8 and 12 weeks.
1. The method of treating drug-resistant mycobacterial infection in an animal comprising administration to the said animal, Penicillin and isoniazid (INH). 2. The method of claim 1 wherein penicillin is administered simultaneously with INH. 3. The method as claimed in claim 1 wherein penicillin and INH are administered sequentially. 4. The method as claimed in claim 1 to 3 wherein penicillin can be a broad spectrum penicillin or a narrow spectrum penicillin. 5. The method as claimed in claim 1 to 4 wherein penicillin can be any single penicillin or combination of more than one penicillin. 6. The method as claimed in claim 1 to 5 wherein penicillin can have activity against beta-lactamase producing organism. 7. The method as claimed in claim 1 to 4 wherein penicillin can be active against penicillinase producing organisms. 8. The method as claimed in claim 1 to 5 wherein penicillins can be selected from the group of penicillin comprising Benzylpenicillin, Phenoxymethylpenicillin, Propicillin, Clemizole penicillin, Procaine penicillin, Phenethicillin, Hetacillin, Metampicillin, Pivampicillin, Cyclacillin, Epicillin, Pevmecillinam, Apalcillin, Aspoxicillin, Temocillin, Methicillin, Oxacillin, Nafcillin, Ampicillin, Amoxycillin, Carbenicillin, Ticarcillin, Azlocillin, Mezlocillin, Piperacillin, Cloxacillin, Dicloxacillin, Lenampicillin, Bacampicillin, Azidocillin, Talampicillin, Mecillinam, Flucloxacillin, Aztreonam, Imipenem, Meropenem and the like. 9. The method as claimed in claim 1 wherein penicillin can be administered by oral, parenteral or rectal route. 10. The method as claimed in claim 1 wherein penicillin can be administered separately or as a single fixed dose combination.
PURPOSE: A manufacturing method of cleaning solution for washing nasal cavity is provided which prevents acute rhinitis, chronic rhinitis, etiologh, and so forth. CONSTITUTION: A cleaning solution comprises 100% of botanic raw materials of which 90%are used as herb medicine. The main components of cleaning solution are Sanguisorbae radix, liquorice root, and Saururus chinessis. Other components are elm root, green tea leaf, magnolia flower bud and ethanol. Minor component are peppermint, sponge gourd root, ginger, plantain stem, salt, and aroma favor extracted from fragrant plants. A method for manufacturing the cleaning solution is characterized by comprising the steps and methods of: mixing botanic raw materials adding spirits therein; condensing and then isolating; and mixing many other herb medicines.
Only mothers will receive face-to-face theoretical breastfeeding training followed by practical training (breastfeeding techniques, flatulence, changing diapers, milking by hand or pump, etc.). This training is planned to take 30-45 minutes. At the end of the training, mothers will be given a "Breastfeeding Booklet" prepared by the researchers.
OBJECTIVE: To observe the effects of electroacupuncture (EA) on sleep quality, sleep structure, and cognitive function in patients with insomnia related to cerebral infarction, and to explore the brain effect mechanism of EA on insomnia related to cerebral infarction.
METHODS: Thirty-six patients with insomnia related to cerebral infarction were randomly divided into an EA group (18 cases, 1 case was eliminated and 1 case dropped out) and a sham acupuncture group (18 cases, 1 case was eliminated and 2 cases dropped out). Both groups received conventional treatment for cerebral infarction. The EA group received EA at Sishencong (EX-HN 1) with continuous waves at a frequency of 2 Hz, at an intensity tolerable to the patient. The sham acupuncture group received sham acupuncture at non-acupoints with the same EA parameters but electrical stimulation was interrupted after 30 s. Both groups were treated for 20 min each session, once daily, 5 days per week, for a total of 4 weeks. Pittsburgh sleep quality index (PSQI), Montreal cognitive assessment-basic (MoCA-B) scores, and short-term memory (STM) encoding test accuracy and average reaction time were observed before and after treatment in the two groups. Polysomnography (PSG) was used to evaluate sleep structure, and electroencephalogram (EEG) data were collected to observe the standardized power value of the Theta frequency band before and after treatment.
RESULTS: Compared with before treatment, PSQI score was decreased and MoCA-B score was increased in the EA group after treatment (P<0.001); the EA group had lower PSQI score and higher MoCA-B score than those in the sham acupuncture group (P<0.001, P<0.01). Compared with before treatment, STM encoding test accuracy was increased and average reaction time was shortened in the EA group after treatment (P<0.01, P<0.001); sleep efficiency (SE) was increased (P<0.01), total sleep time (TST), REM, and N3 stages were prolonged (P<0.01, P<0.05), and sleep latency (SL) was shortened (P<0.01). The standardized power value of the Theta frequency band in EEG channels F3, C3, C4, O1 and O2 was decreased (P<0.05). After treatment, the EA group had higher STM encoding test accuracy, shorter average reaction time (P<0.05), higher SE (P<0.01), longer TST, REM and N3 stages (P<0.01), and shorter SL (P<0.01) than those in the sham acupuncture group. There was no statistically significant difference in the standardized power value of the Theta frequency band between the two groups (P>0.05).
CONCLUSION: EA could regulate sleep quality and structure in patients with insomnia related to cerebral infarction, and improve cognitive function, possibly related to the reduction of slow-wave activity in EEG.
SIAM III was a multicenter, randomized, prospective, controlled trial in patients with ST-elevation myocardial infarction receiving fibrinolysis \<12 hours after onset of symptoms. All patients received reteplase, aspirin in combination with ticlopidin, and heparin. Patients of the early PCI group were transferred within 6 hours after fibrinolysis for PCI. The conservative group received elective PCI two weeks after fibrinolysis. In total 197 patients were included, 163 were treated by PCI. The primary end point was the composite of ischemic events, death, reinfarction, and target lesion revascularization.
Telemedicine "healing at a distance" Telemedicine has many advantages especially in time of pandemics for both doctors and patients, low cost and easily accessibility. Pandemics especially COVID 19 has radically change the medical team thoughts about the telemedicine. It can decrease the exposure of the medical team to infection and expected by some of the medical team to be very beneficial if done in good and legal manner. Although, telemedicine has many advantages, also has many disadvantages and medicolegal problems, breakdown in the relationship between medical teams and patients, mis diagnosis or wrong treatment. There are many legal and ethical aspects of telemedicine. These include the medical responsibilities, the confidentiality and privacy of the patients can not be maintained, the jurisdictional problems. Shortage of medical practitioners and specialists, shortage of internet facilities, low education levels in some patients all are problems facing the telemedicine in developing countries. The evolution of telemedicine poses a series of legal problems ranging from the profiles on the subject of authorization and accreditation to those concerning the protection of patient confidentiality, the definition and solution of which, in the absence of specific regulatory provisions, is mainly left to the assessment of compatibility of the practices adopted so far, with the general regulatory framework.

This research will be done to clarify the role of telemedicine, and if it has a share hand or the upper hand if compared with traditional medicine.
PURPOSE: A polyethylene glycol-based moisturizing agent containing oxyethylene oxygen is provided to ensure an excellent moisturizing effect and uniform particle size, and to prevent irritation without alcohol and perfume. CONSTITUTION: A moisturizing agent is used for a cosmetic composition. The moisturizing agent contains a polyethylene glycol compound containing oxyethylene oxygen which is bonded with hydrogen from hydroxy group in water. The molecular weight of the polyethylene glycol compound is 200-1100. The polyethylene glycol compound is selected from a group consisting of polyethylene glycol/polypropylene glycol-17/6 copolymer(PEG/PPG-17/6 copolymer), polyethylene glycol/polypropylene glycol/polybutylene glycol-8/5/3 glycerin(PEG/PPG/PBG-8/5/3 glycerin), and glycereth-26. The cosmetic composition contains 5-10 wt% of the moisturizing agent and remaining amount of distilled water. The cosmetic composition is applied by being applied onto the skin a user.
Neuroleptic Malignant Syndrome (NMS), a potentially fatal symptom complex, has been reported in association with antipsychotic drugs. Clinical manifestations of NMS are hyperpyrexia, muscle rigidity, altered mental status including delirium, and autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis, and cardiac dysrhythmia). Additional signs may include elevated creatine phosphokinase, myoglobinuria (rhabdomyolysis), and acute renal failure. Neuroleptic Malignant Syndrome (NMS), a potentially fatal symptom complex, has been reported in association with antipsychotic drugs. Clinical manifestations of NMS are hyperpyrexia, muscle rigidity, altered mental status including delirium, and autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis, and cardiac dysrhythmia). Additional signs may include elevated creatine phosphokinase, myoglobinuria (rhabdomyolysis), and acute renal failure.    
If NMS is suspected, immediately discontinue risperidone and provide symptomatic treatment and monitoring.
Caretakers of 10 children will be randomized to participate in the control group. Participants assigned to the control group will be able to receive the iEAT treatment after the study ends.
We are examining changes in brain structure and function as predictors of cognitive decline and impairment through longitudinal neuroimaging assessments of selected Baltimore Longitudinal Study of Aging (BLSA) participants. The hypothesis driving this study is that accelerated preclinical changes in brain structure and function in specific regions, including mesial temporal cortex, cingulate cortex, and inferior parietal cortex, will predict which individuals subsequently develop cognitive impairment and Alzheimer s disease. Since 1994, magnetic resonance imaging (MRI), positron emission tomography (PET), and neuropsychological testing have been performed for the neuroimaging participants, aged 55 and older. In the next phase of this study, we will continue longitudinal testing of older participants and will continue enrolling additional participants. We will continue MRI studies of brain structure, with enhanced measures of vascular changes, and will perform PET studies of cerebral blood flow, amyloid distribution in brain, and, in a subset of participants, cerebral glucose metabolism. We will also extend the MRI and neuropsychological evaluations to an additional 60 BLSA participants aged 20 to 54. Our initial data indicate substantial changes in brain volumes and tissue composition through the 5th evaluation, despite only minimal cognitive change in this generally healthy sample. We will continue to follow these individuals and will examine modifiers of both structural and functional brain changes and their associations with cognitive decline. Potential modulators include genetic factors, hormonal status and therapies, medications, dietary supplements, and other health-related factors. We have already observed acceleration of hippocampal volume loss in individuals at increased genetic risk for Alzheimer s disease, carriers of the apolipoprotein E epsilon 4 allele, and modulation of memory and regional cerebral blood flow activation patterns as a function of postmenopausal hormone therapy in women and endogenous testosterone concentrations in men. We will continue to examine these and other modifiers of brain-behavior associations. Early prediction of cognitive impairment and factors that alter the incidence or progression of disease will be essential as new therapies are on the horizon.
Pain in adolescence can lead to the development of serious mental health issues, including suicidality. This risk may be strengthened among youth exposed to more adverse childhood experiences (ACEs; abuse, neglect, household challenges). This longitudinal study examined the role of ACEs in the relationship between pain and later suicidality onset and severity among a cohort of adolescents at risk for developing mental health problems. Participants were 139 healthy youth (Mage = 13.74 years, standard deviation = 1.56, 64% female) between the ages of 11 to 17 years, recruited based on parental history of depression or anxiety. Youth completed validated measures of internalizing symptoms, ACEs, and pain characteristics at baseline and follow-up diagnostic interviews 9 and/or 18 months later to assess for onset and severity of suicidality. After controlling for demographics, baseline internalizing symptoms, and ACEs, worse pain interference and increased ACEs at baseline predicted increased suicidality severity at follow-up. Moderation analyses revealed that there was a significant interaction between ACEs and pain interference and pain intensity. Increased pain interference (b = 7.65, P < .0001) or intensity (b = 6.96, P = .0003) was only associated with increased suicidality severity at follow-up in youth with high levels of ACEs. This study demonstrates that ACEs strengthen the relationship between pain and later suicidality severity among youth at risk of developing mental health problems. Findings underscore the critical need to adopt a trauma-informed lens to pediatric pain prevention and treatment (eg, screening for ACEs) and for the pain to be on the child's mental health agenda. PERSPECTIVE: This article provides evidence that, while pain is a risk factor for future increased suicidality severity, it is a particularly strong risk factor in youth who experienced increased childhood adversity. These results may help identify youth at greatest risk for suicidality.
Amino compds. of pyridazines of formula (I) and their salts with pharmaceutically acceptable acids are prepared by reacting the corresp. substd. 3-chloro pyridazine with an amine H2N-A-NH-X, in the precence of hydronic acid water at about b.p of solvent in alcoholic solvent.  In formula, R1 is H or 1-4C alkyl, R2 is H, R3 is phenyl or hydroxyphenyl, A is 2-5C linear or branchd alkylene, X is H or 1-4C alkyl.  These cpds are useful for the treatment of psychomotor behavioural disorders.
A system, a method, and an electronic platform provide co-management of two or more healthcare practices, such as an ophthalmology practice and an optometry practice. In one aspect, the disclosure provides for a method including retrieving an electronic health record for a patient and storing first health information for the patient corresponding to a diagnosis of the patient by the first healthcare practice. The patient is referred to the second healthcare practice in response to the diagnosis of the patient, corresponding to treatment provided by the second healthcare practice. The electronic health record and the health information are provided to the second healthcare practice, and second health information is stored for the patient corresponding to treatment of the patient by the second healthcare practice. At least one follow-up visit is scheduled for the patient at one of the first healthcare practice or the second healthcare practice. A first portion of a referral fee from the second healthcare practice is distributed to the first healthcare practice, and a second portion of the referral fee is distributed to a co-management system provider.
No animal carcinogenicity studies with fludarabine have been conducted.

Fludarabine phosphate was clastogenic in vitro to Chinese hamster ovary cells (chromosome aberrations in the presence of metabolic activation) and induced sister chromatid exchanges both with and without metabolic activation. In addition, fludarabine phosphate was clastogenic in vivo (mouse micronucleus assay) but was not mutagenic to germ cells (dominant lethal test in male mice). Fludarabine phosphate was not mutagenic to bacteria (Ames test) or mammalian cells (HGRPT assay in Chinese hamster ovary cells) either in the presence or absence of metabolic activation. 

Studies in mice, rats and dogs have demonstrated dose-related adverse effects on the male reproductive system. Observations consisted of a decrease in mean testicular weights in mice and rats with a trend toward decreased testicular weights in dogs and degeneration and necrosis of spermatogenic epithelium of the testes in mice, rats and dogs. The possible adverse effects on fertility in humans have not been adequately evaluated [see Warnings and Precautions (5.7)].
This is a multi-disciplinary research study with five investigators from different, yet complementary, disciplines to establish this new collaboration. There is a high translational potential for information gained from this project based on the collaboration of a rheumatologist, a dentist, oral biologists, and infectious disease experts with expertise in immunology, microbiology, and genomics. In brief, RA participants will be recruited by the rheumatologist. A total of 100 participants will be recruited for two groups to be studied; one group of subjects with RA and the other group will be healthy controls. These two groups will be divided into the following groups for participation in the study: Group 1: will consist of 25 RA adult subjects who have not been treated with biologics which will be compared to 25 healthy controls from age-matched members of the same household. Group 2 will consist of 25 RA adult subjects responsive to first line anti-TNF therapy which will be compared to 25 subjects of the same age and sex with RA who are resistant to two or more TNF antagonists. The participants will be scheduled for a research study visit at the University of Florida Dental Clinic Research Unit. During the exam the following will take place: the multidimensional health assessment questionnaire (MDHAQ), dental exam, saliva collection, and dental plaque will be removed from different tooth surfaces for supragingival.

The supragingival will be subjected to deep sequencing in the genomics lab. To test two specific aims: 1) testing the hypothesis that oral microbiome profiles based on 16S RNA data are associated with the development of RA or with the response to a specific therapy, and 2) testing the hypothesis that the specific genes, variants, and functional capabilities (metagenome) are associated with RA or with therapeutic response. Upon completion of this pilot study, the investigators will have systematically identified bacterial biomarkers (e.g. species, subspecies, genes) that correlate with RA and may serve as potential targets for disease treatment. These markers may be developed into new drug targets for RA therapy in future studies.